Do analysts rate TLRY or RFAI?

Tilray Brands presently has a consensus target price of $7.00, suggesting a potential upside of 70.32%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, TLRY or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tilray Brands $915.45M 0.61 -$121.40M -$1.08 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Does the media favor TLRY or RFAI?

In the previous week, Tilray Brands had 18 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 19 mentions for Tilray Brands and 1 mentions for RF Acquisition Corp II. Tilray Brands' average media sentiment score of 0.18 beat RF Acquisition Corp II's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral RF Acquisition Corp II 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RFAI or EOLS?

Evolus has a consensus price target of $14.50, indicating a potential upside of 81.25%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, RFAI or EOLS?

RF Acquisition Corp II has higher earnings, but lower revenue than Evolus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A Evolus $297.18M 1.78 -$51.64M -$0.52 N/A

Is RFAI or EOLS more profitable?

RF Acquisition Corp II has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Company Net Margins Return on Equity Return on Assets RF Acquisition Corp II N/A N/A N/A Evolus -10.85% N/A -13.00%

Does the media prefer RFAI or EOLS?

In the previous week, Evolus had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 2 mentions for Evolus and 1 mentions for RF Acquisition Corp II. Evolus' average media sentiment score of 0.51 beat RF Acquisition Corp II's score of 0.00 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RF Acquisition Corp II 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RFAI or OVID?

Ovid Therapeutics has a consensus target price of $6.00, indicating a potential upside of 133.46%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ovid Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90

Which has higher earnings and valuation, RFAI or OVID?

RF Acquisition Corp II has higher earnings, but lower revenue than Ovid Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A Ovid Therapeutics $7.25M 69.23 -$17.41M -$0.31 N/A

Which has higher valuation and earnings, ASMB or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Assembly Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assembly Biosciences $72.30M 6.75 -$6.12M $1.02 23.50 RF Acquisition Corp II N/A N/A N/A N/A N/A

Does the media favor ASMB or RFAI?

In the previous week, Assembly Biosciences and Assembly Biosciences both had 1 articles in the media. Assembly Biosciences' average media sentiment score of 1.04 beat RF Acquisition Corp II's score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RF Acquisition Corp II 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CTNM or RFAI?

Contineum Therapeutics presently has a consensus target price of $20.80, suggesting a potential upside of 66.27%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Contineum Therapeutics is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, CTNM or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Contineum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Contineum Therapeutics $50M 9.41 -$59.98M -$1.73 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is CTNM or RFAI more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% RF Acquisition Corp II N/A N/A N/A

Does the media refer more to CTNM or RFAI?

In the previous week, Contineum Therapeutics had 6 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 7 mentions for Contineum Therapeutics and 1 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 0.00 beat Contineum Therapeutics' score of -0.14 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral RF Acquisition Corp II 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

RF Acquisition Corp II (RFAI) Competitors

$34.22 -1.78 (-4.94%)

Closing price 09/23/2026 03:53 PM Eastern

Extended Trading

$34.10 -0.12 (-0.36%)

As of 04:03 AM Eastern

Compare

RFAI vs. TLRY, EOLS, OVID, ASMB, and CTNM

Should you buy RF Acquisition Corp II stock or one of its competitors? RF Acquisition Corp II's main competitors and comparable companies include Tilray Brands (TLRY), Evolus (EOLS), Ovid Therapeutics (OVID), Assembly Biosciences (ASMB), and Contineum Therapeutics (CTNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does RF Acquisition Corp II compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

9.4% of Tilray Brands shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tilray Brands has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

RF Acquisition Corp II has lower revenue, but higher earnings than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.61	-$121.40M	-$1.08	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

RF Acquisition Corp II has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. RF Acquisition Corp II's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
RF Acquisition Corp II	N/A	N/A	N/A

In the previous week, Tilray Brands had 18 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 19 mentions for Tilray Brands and 1 mentions for RF Acquisition Corp II. Tilray Brands' average media sentiment score of 0.18 beat RF Acquisition Corp II's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
RF Acquisition Corp II	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands presently has a consensus target price of $7.00, suggesting a potential upside of 70.32%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tilray Brands beats RF Acquisition Corp II on 9 of the 13 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Evolus?

RF Acquisition Corp II (NASDAQ:RFAI) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Evolus has a consensus price target of $14.50, indicating a potential upside of 81.25%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

RF Acquisition Corp II has a net margin of 0.00% compared to Evolus' net margin of -10.85%.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
Evolus	-10.85%	N/A	-13.00%

In the previous week, Evolus had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 2 mentions for Evolus and 1 mentions for RF Acquisition Corp II. Evolus' average media sentiment score of 0.51 beat RF Acquisition Corp II's score of 0.00 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RF Acquisition Corp II	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RF Acquisition Corp II has higher earnings, but lower revenue than Evolus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
Evolus	$297.18M	1.78	-$51.64M	-$0.52	N/A

90.7% of Evolus shares are held by institutional investors. 39.1% of RF Acquisition Corp II shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

RF Acquisition Corp II has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Evolus has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Summary

Evolus beats RF Acquisition Corp II on 8 of the 11 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Ovid Therapeutics?

RF Acquisition Corp II (NASDAQ:RFAI) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

RF Acquisition Corp II has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. RF Acquisition Corp II's return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

In the previous week, RF Acquisition Corp II had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 1 mentions for RF Acquisition Corp II and 0 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.34 beat RF Acquisition Corp II's score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
RF Acquisition Corp II	Neutral
Ovid Therapeutics	Neutral

RF Acquisition Corp II has higher earnings, but lower revenue than Ovid Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
Ovid Therapeutics	$7.25M	69.23	-$17.41M	-$0.31	N/A

RF Acquisition Corp II has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

72.2% of Ovid Therapeutics shares are held by institutional investors. 39.1% of RF Acquisition Corp II shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ovid Therapeutics has a consensus target price of $6.00, indicating a potential upside of 133.46%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Ovid Therapeutics beats RF Acquisition Corp II on 7 of the 13 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

RF Acquisition Corp II has lower revenue, but higher earnings than Assembly Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.75	-$6.12M	$1.02	23.50
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Assembly Biosciences presently has a consensus price target of $47.50, suggesting a potential upside of 98.16%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Assembly Biosciences is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RF Acquisition Corp II has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. RF Acquisition Corp II's return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
RF Acquisition Corp II	N/A	N/A	N/A

In the previous week, Assembly Biosciences and Assembly Biosciences both had 1 articles in the media. Assembly Biosciences' average media sentiment score of 1.04 beat RF Acquisition Corp II's score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RF Acquisition Corp II	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Assembly Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

19.9% of Assembly Biosciences shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Assembly Biosciences beats RF Acquisition Corp II on 7 of the 12 factors compared between the two stocks.

How does RF Acquisition Corp II compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

RF Acquisition Corp II's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
RF Acquisition Corp II	N/A	N/A	N/A

In the previous week, Contineum Therapeutics had 6 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 7 mentions for Contineum Therapeutics and 1 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 0.00 beat Contineum Therapeutics' score of -0.14 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
RF Acquisition Corp II	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Contineum Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

RF Acquisition Corp II has lower revenue, but higher earnings than Contineum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	9.41	-$59.98M	-$1.73	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Contineum Therapeutics presently has a consensus target price of $20.80, suggesting a potential upside of 66.27%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Contineum Therapeutics is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Contineum Therapeutics beats RF Acquisition Corp II on 5 of the 9 factors compared between the two stocks.

Get RF Acquisition Corp II News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RFAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RFAI vs. The Competition

Export

Metric	RF Acquisition Corp II	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$126.45M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	N/A	792.28	274.09	25.69
Price / Sales	N/A	861.37	642.55	79.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	N/A	10.58	10.47	6.32
Net Income	N/A	$2.81B	$3.49B	$359.73M
7 Day Performance	-16.78%	-0.12%	-0.68%	0.17%
1 Month Performance	-32.95%	-1.34%	-3.18%	-3.27%
1 Year Performance	221.62%	2.86%	15.12%	5.58%

RF Acquisition Corp II Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RFAI RF Acquisition Corp II	0.9335 of 5 stars	$34.22 -4.9%	N/A	+221.6%	$126.45M	N/A	N/A	2	Gap Down
TLRY Tilray Brands	3.9622 of 5 stars	$3.99 +1.3%	$8.00 +100.5%	-66.9%	$536.64M	$915.45M	N/A	3,595	Analyst Forecast
EOLS Evolus	2.7093 of 5 stars	$7.86 -1.9%	$14.50 +84.5%	+29.2%	$529.06M	$297.18M	N/A	353	Positive News
OVID Ovid Therapeutics	2.4217 of 5 stars	$2.69 -0.4%	$6.00 +123.0%	+104.0%	$527.30M	$7.25M	N/A	23	High Trading Volume
ASMB Assembly Biosciences	3.8103 of 5 stars	$24.97 -1.5%	$45.60 +82.6%	-7.8%	$515.94M	$72.30M	24.48	73	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RFAI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RF Acquisition Corp II (RFAI) Competitors

RFAI vs. TLRY, EOLS, OVID, ASMB, and CTNM

How does RF Acquisition Corp II compare to Tilray Brands?

Summary

How does RF Acquisition Corp II compare to Evolus?

Summary

How does RF Acquisition Corp II compare to Ovid Therapeutics?

Summary

How does RF Acquisition Corp II compare to Assembly Biosciences?

Summary

How does RF Acquisition Corp II compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI vs. The Competition

RF Acquisition Corp II Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RF Acquisition Corp II (RFAI) Competitors

RFAI vs. TLRY, EOLS, OVID, ASMB, and CTNM

How does RF Acquisition Corp II compare to Tilray Brands?

Do insiders and institutionals hold more shares of TLRY or RFAI?

Which has more volatility & risk, TLRY or RFAI?

Which has higher earnings & valuation, TLRY or RFAI?

Is TLRY or RFAI more profitable?

Does the media favor TLRY or RFAI?

Do analysts rate TLRY or RFAI?

Summary

How does RF Acquisition Corp II compare to Evolus?

Do analysts prefer RFAI or EOLS?

Is RFAI or EOLS more profitable?

Does the media prefer RFAI or EOLS?

Which has higher valuation and earnings, RFAI or EOLS?

Do institutionals and insiders have more ownership in RFAI or EOLS?

Which has more risk and volatility, RFAI or EOLS?

Summary

How does RF Acquisition Corp II compare to Ovid Therapeutics?

Is RFAI or OVID more profitable?

Does the media refer more to RFAI or OVID?

Which has higher earnings and valuation, RFAI or OVID?

Which has more risk and volatility, RFAI or OVID?

Do institutionals & insiders have more ownership in RFAI or OVID?

Do analysts rate RFAI or OVID?

Summary

How does RF Acquisition Corp II compare to Assembly Biosciences?

Which has higher valuation and earnings, ASMB or RFAI?

Do analysts rate ASMB or RFAI?

Is ASMB or RFAI more profitable?

Does the media favor ASMB or RFAI?

Which has more volatility and risk, ASMB or RFAI?

Do institutionals and insiders believe in ASMB or RFAI?

Summary

How does RF Acquisition Corp II compare to Contineum Therapeutics?

Is CTNM or RFAI more profitable?

Does the media refer more to CTNM or RFAI?

Which has more risk and volatility, CTNM or RFAI?

Which has preferable earnings & valuation, CTNM or RFAI?

Do analysts recommend CTNM or RFAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI vs. The Competition

RF Acquisition Corp II Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools